Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use
Biomolecules · 2025
DOI: 10.3390/biom15020224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Yulia Ilina und 4 weiteren Autor:innen. Beteiligte Einrichtung: PAM Theragnostics GmbH, 16761 Hennigsdorf, Germany. Hauptthemen laut MEDLINE: Mixed Function Oxygenases, Multienzyme Complexes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Peptidylglycine alpha-amidating monooxygenase (PAM) is the only enzyme known to catalyze C-terminal amidation, a final post-translational modification step essential for the biological activity of over 70 bioactive peptides, including adrenomedullin (ADM), calcitonin gene-related peptide (CGRP), amylin, neuropeptide Y (NPY), and others. Bioactive (amidated) peptide hormones play crucial roles in various physiological processes and have been extensively explored as therapeutic compounds in clinical and preclinical research. However, their therapeutic viability is limited due to their short half-life and, in most cases, the need for prolonged infusion to maintain effective concentrations. PAM itself has also been considered as a therapeutic compound aiming to increase the level of amidated peptide hormones; however, similarly to peptide hormones, PAM’s rapid degradation limits its utility. Here, we present a strategy to enhance PAM stability and bioavailability through PEGylation, significantly extending the enzyme’s half-life in circulation assessed in healthy rats. Furthermore, single subcutaneous (s.c.), intramuscular (i.m.), or intraperitoneal (i.p.) administration of PEGylated PAM resulted in a sustained increase in circulating amidating activity, with peak activity observed at 12–24 h post-bolus administration. Notably, amidating activity remained significantly elevated above baseline levels for up to seven days post-administration, with no observable adverse effects. These findings highlight PEGylated PAM’s potential as a viable therapeutic compound.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PAM Theragnostics GmbH, 16761 Hennigsdorf, Germany.
- 4TEEN4 Pharmaceuticals GmbH, 16761 Hennigsdorf, Germany.
Zitieren
APA
Ilina, Y., Kaufmann, P., Press, M., Uba, T. I., & Bergmann, A. (2025). Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use. Biomolecules. https://doi.org/10.3390/biom15020224
Vancouver
Ilina Y, Kaufmann P, Press M, Uba TI, Bergmann A. Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use. Biomolecules. 2025. doi:10.3390/biom15020224
BibTeX
@article{Ilina2025,
author = {Ilina, Yulia and Kaufmann, Paul and Press, Michaela and Uba, Theo Ikenna and Bergmann, Andreas},
title = {Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15020224}
}
EUVIMED